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After radiotherapy for pelvic cancer, chronic gastrointestinal problems may affect quality of life (QOL) in 6–78% of patients. This
variation may be due to true differences in outcome in different diseases, and may also represent the inadequacy of the scales used to
measure radiotherapy-induced gastrointestinal side effects. The aim of this study was to assess whether outcome measures used for
nonmalignant gastrointestinal disease are useful to detect gastrointestinal morbidity after radiotherapy. Results obtained from a Vaizey
Incontinence questionnaire and a modified Inflammatory Bowel Disease questionnaire (IBDQ) – both patient completed – were
compared to those from a staff administered Late Effects on Normal Tissue (LENT) – Subjective, Objective, Management and
Analytic (SOMA) questionnaire in patients who had completed radiotherapy for a pelvic tumour at least 3 months previously. In all,
142 consecutive patients were recruited, 72 male and 70 female, median age 66 years (range 26–90 years), a median of 27 (range
3–258) months after radiotherapy. In total, 62 had been treated for a gynaecological, 58, a urological and 22, a gastrointestinal tract
tumour. Of these, 21 had undergone previous gastrointestinal surgery and seven suffered chronic gastrointestinal disorders preceding
their diagnosis of cancer. The Vaizey questionnaire suggested that 27% patients were incontinent for solid stools, 35% for liquid stools
and 37% could not defer defaecation for 15min. The IBDQ suggested that 89% had developed a chronic change in bowel habit and
this change significantly affected 49% patients: 44% had more frequent or looser bowel movements, 30% were troubled by
abdominal pain, 30% were troubled by bloating, 28% complained of tenesmus, 27% were troubled by their accidental soiling and 20%
had rectal bleeding. At least 34% suffered emotional distress and 22% impairment of social function because of their bowels. The
small intestine/colon SOMA median score was 0.1538 (range 0–1) and the rectal SOMA median score was 0.1428 (range 0–1).
Pearson’s correlations for the IBDQ score and small intestine/colon SOMA score was  0.630 (Po0.001), IBDQ and rectum SOMA
 0.616 (Po0.001), IBDQ and Vaizey scores  0.599 (Po0.001), Vaizey and small intestine/colon SOMA 0.452 (Po0.001) and
Vaizey and rectum SOMA 0.760 (Po0.001). After radiotherapy for a tumour in the pelvis, half of all patients develop gastrointestinal
morbidity, which affects their QOL. A modified IBDQ and Vaizey questionnaire are reliable in assessing new gastrointestinal
symptoms as well as overall QOL and are much easier to use than LENT SOMA.
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Quality of life (QOL) measures are important in the management
of patients with malignant disease. These measures must be
reliable and convenient to use and should assess physical,
functional, social and emotional well-being (Cella et al, 2002).
Cancer treatments are becoming increasingly successful at
obtaining long-term palliation and cure. In order to define and
offer optimal treatments and perhaps to define which patients
require further specialist evaluation or support after treatment, it
is very important to measure QOL and chronic adverse treatment
effects accurately.
Radiotherapy is used in the treatment of four out of 10 cancer
patients. In the UK, this includes about 12000 patients who receive
radiotherapy for pelvic cancer, mainly with curative intent.
However, the frequency with which pelvic radiotherapy leads to
side effects affecting QOL is not known. The literature suggests
that it ranges from 6 to 78% of patients (Kollmorgen et al, 1994;
Potosky et al, 2000; Gami et al, 2003; Kozelsky et al, 2003). This
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svariation may reflect a true difference in chronic toxicity in
different diseases using different techniques. It seems more likely,
however, that this degree of variation reflects the inadequacy of
currently used toxicity scales. Indeed, the CTC Version 2, the
Dische system, Franco-Italian Glossary, UCLA Cancer Index and
RTOG/EORTC have all been shown to have shortcomings
(Shakespeare et al, 1998; Yeoh et al, 2000; Anacak et al, 2001;
Livsey et al, 2002; Trotti, 2002). More recently, the Late Effects
Normal Tissue (LENT) SOMA questionnaire (Pavy et al, 1995;
Rubin et al, 1995) has been proposed, and while overcoming many
of the problems of earlier questionnaires, it is much more complex
and requires a lengthy, structured interview with a patient, which
is often not feasible.
In general, evaluations of gastrointestinal toxicity after radio-
therapy have failed to draw on experience gained by gastroenter-
ologists in designing scoring systems to judge severity of
nonmalignant gastrointestinal diseases. Inflammatory diseases
such as ulcerative colitis and Crohn’s disease can produce many
of the same symptoms as radiotherapy toxicity. Of the many
questionnaires developed for evaluation of outcome in these
conditions, the Inflammatory Bowel Disease questionnaire (IBDQ)
does not require an interview and can be completed by a patient
within a few minutes. It is a good predictor of severity of disease
and in addition provides a score for QOL (Guyatt et al, 1989). The
questions used in the IBDQ reflect those aspects of the disease that
are recognised by patients and health professionals alike as
frequent and important problems. These include bowel symptoms,
systemic symptoms, emotional function and social function. In
addition, it is clear that patients find the IBDQ easy to understand.
A second questionnaire, the Vaizey incontinence score, again
completed by most patients within 2–3min has been shown to
outperform other questionnaires as a simple and accurate way of
detecting faecal incontinence (Vaizey et al, 1999).
The aim of this study was to assess whether the IBDQ and
Vaizey Incontinence questionnaire, two simple patient completed
questionnaires, could accurately assess the degree of gastrointest-
inal chronic toxicity and disability experienced after pelvic
radiotherapy.
Table 1 The modified IBDQ
In the last 2 weeks please tell us how
often you have:
More than
ever before
Extremely
frequently
Very
frequently
Moderate
increase in
frequency
Some
increase in
frequency
Slight
increase in
frequency
Not at all/
normal
1 Had your bowel open?
2 Felt tired and worn out?
3 Felt frustrated, impatient or restless?
4 Been unable to do what you want because of
your bowels?
5 Had loose bowel movements?
6 Worried about your energy levels?
7 Worried about having to have something done
about your bowels?
8 You had to cancel an engagement because of
your bowels?
9 Been troubled by pain in your bottom?
10 Felt generally unwell?
11 Worried about not being able to find a
lavatory?
12 Been prevented doing leisure or sports by your
bowels?
13 Been troubled by pain in your tummy or
bottom?
14 Been waking at night or having difficulty
sleeping?
15 Been depressed or discouraged?
16 Not gone somewhere because there is no
lavatory nearby?
17 Passed large amounts of gas?
18 Worried about getting to the weight you would
like?
19 Worried about your illness?
20 Been troubled by bloating?
21 Been relaxed and free of tension?
22 Had a problem with bleeding from your
bottom?
23 Been embarrassed about your bowels?
24 Felt like you need to have your bowels open
but nothing happens?
25 Felt tearful and upset?
26 Been troubled by accidental soiling?
27 Felt angry as a result of your bowel problems?
28 Felt limited in sexual activity because of your
bowels?
29 Felt disgusted about your bowel problems?
30 Felt irritable?
31 Experienced lack of understanding from others?
32 Felt satisfied, happy or pleased with your life?
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sPATIENTS AND METHODS
The population studied had completed radiotherapy for a pelvic
cancer 3 months or more previously. Patients who had received
radiotherapy for gynaecological, bladder, prostate or rectosigmoid
or anal cancers were recruited from outpatient follow-up clinics at
the Royal Marsden Hospital in London and Surrey, UK. Eligible
patients were enrolled after providing informed consent. The study
was reviewed and approved by the Royal Marsden Research and
Ethics Committees.
Patients’ age, primary tumour site, date of diagnosis, current
disease status and any previous bowel surgery or chronic
gastrointestinal disease were recorded. Each patient was asked to
fill in the IBDQ and Vaizey questionnaires. Then an assessment of
bowel toxicity was made using the LENT SOMA questionnaire in a
structured interview.
The IBDQ contains 32 questions. Each question is scored 1–7
according to the severity of symptoms. Patients score 7 if the
symptom asked about is absent or has not changed since before
radiotherapy. They score 1 if that symptom is the worst possible.
Thus, the highest attainable score is 224, suggesting that the
patient is asymptomatic and the lowest attainable score is 32,
suggesting that the patient is very severely symptomatic. The IBDQ
as initially described includes five questions on systemic
symptoms joint, skin or eye problems – which some patients with
inflammatory bowel disease sometimes develop. These questions
were modified before use in this study. The modified IBDQ is
shown in Table 1. In addition to an overall symptom score, the
IBDQ provides a QOL score by assessing emotional and social
function.
The Vaizey Incontinence questionnaire consists of seven
questions. These are scored as shown in Table 2. A score of 0
suggests no problems with bowel continence, and a score of 24
suggests very severe problems with incontinence.
The LENT SOMA scores are obtained after completing a series
of questions, which grade subjective and objective symptoms and
score for the requirement for medical intervention. Small bowel/
colon and rectal scores can then be summed and divided by the
total number of questions to give a overall score of between 0 (no
symptoms) and 5 (fatal toxicity).
Statistics
We hypothesised that as patients with different types of pelvic
cancer receive different types of therapy, they might develop a
different profile of symptoms following therapy. To examine
whether these questionnaires measured chronic toxicity accurately
for different pelvic cancers, we calculated that 47 gynaecological or
bladder patients, 47 prostate patients and 47 lower gastrointestinal
patients would be sufficient to allow a correlation coefficient of
r¼0.45 to be detected within each group with 90% power. If the
groups were then combined, this would allow a correlation of
r¼0.25 to be detected. Associations between categorical data were
examined using the w
2 test.
RESULTS
Patient characteristics
During July and August 2003, 142 consecutive patients were
recruited onto the study; 62 had been treated for a gynaecological
Table 2 Vaizey questionnaire
Never Rarely Sometimes Weekly Daily
Incontinence for solid stool 0 1 2 3 4
Incontinence for liquid stool 0 1 2 3 4
Incontinence for gas 0 1 2 3 4
Alteration to lifestyle 0 1 2 3 4
No Yes
Need to wear a pad or plug 0 2
Taking constipating medicines 0 2
Lack of ability to defer defecation for 15min 0 4
Never¼no episodes in past 4 weeks; Rarely¼1 episode in past 4 weeks; Sometimes¼41 episode in past 4 weeks but o1 a week; Weekly¼1 or more episodes a week but
o1 a day; Daily¼1 or more episodes a day; Minimum score¼0¼perfect continence; Maximum score¼24¼total incontinence.
Table 3 Patient characteristics
Gynaecology Urology GI Total
No. of patients (%) 62 (44) 58 (41) 22 (15) 142
Median age (years) 59.5 69 67 66
Range 27–90 26–83 51–80 26–90
Tumour site
Anal — — 8
Caecum — — 3
Colon — — 1
Rectum — — 9
Other — — 1
Cervix 22 — —
Uterus 32 — —
Vulva 5 — —
Vagina 2 — —
Bartholin’s 1 — —
Prostate — 56 —
Seminoma — 2 —
Median time since diagnosis
(months)
31 48 36 32
Range 5–258 8–133 7–159 5–258
Median time since radiotherapy
(months)
26 32 23 27
Range 4–258 3–119 3–157 3–258
Bowel history
Anal stretch — 1 — 1
Colitis 1 — — 1
Diverticulitis — 2 1 3
Haemorrhoidectomy — 3 — 3
Irritable bowel — 1 1 2
Intussusception — 1 — 1
Polypectomy — 1 — 1
Bowel resection 2 2 12 16
None 59 47 8 114
Current disease status
No evidence 54 48 19 121
Quiescent 4 8 2 14
Progressive 4 2 1 7
GI¼gastrointestinal.
Identification of gastrointestinal symptoms
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scancer, 58 for a urological cancer and 22 for a cancer in the
gastrointestinal tract within the pelvis. Their characteristics are
shown in Table 3. Time from diagnosis was between 5 and 258
months (median 32 months). All 142 patients had started
radiotherapy at least 3 months beforehand (median 27 months,
range 3–258 months). Each interview took approximately 15min.
Radiotherapy technique and dose prescription
A variety of radiotherapy techniques were used in different patient
groups according to tumour type. The typical protocols are
summarised in Table 4, although treatments and doses were
individualised for each patient. External beam radiotherapy was
delivered by a linear accelerator delivering megavoltage photons at
an energy of 4–10MV.
The Vaizey Incontinence questionnaire
The results obtained from the Vaizey questionnaire are shown in
Table 5. These suggest that overall 55 (39%) patients were
incontinent for solid or liquid stools, and that 23% (55% of these)
felt their incontinence altered their lifestyle. Faecal incontinence
occurred in 50% of those treated for gynaecological cancer (95%
confidence intervals 37–63%) and in 50% of those with a
Table 4 Typical radiotherapy parameters for pelvic treatment sites
Tumour
site
Patient
position
Planning
technique
Typical beam
arrangement
Total dose
(Gy)
Fraction size
(Gy)
Approx
field Brachytherapy
Bladder Supine Conformal CT Anterior 64 2 10 10 —
Opposed laterals
AP:PA:Lats
Prostate Supine Conformal CT 3 field: 64–70 2 9 9—
2 phase Anterior
Opposed laterals 6 6
6 field: 7boost to 74
Laterals
Ant/post obliques
Testis Supine Simulated AP:PA 20–30 2 10 15–30
Bony anatomy Para-aortic dogleg
Anal canal Prone Simulated AP:PA 45 1.8 15 20 —
Bony anatomy 3 field 15
Direct electron implant
Rectum Prone Conformal CT 3 field: 45 1.8 17 17 —
2 phase Post 17 10
Opposed laterals 5.4–9 1.8 10 10
Uterus Supine Simulated 3 field: 45 1.8 16 16 Ir-192
Bony anatomy Anterior HDR
Opposed laterals 8Gy in two insertions at 0.5cm
Vulva/vagina Supine Simulated AP:PA 45 1.8 15 20 —
Bony anatomy 3 field
Cervix Supine Simulated 3 field: 45–50.4 1.8 24 16 Cs 137
Bony anatomy Anterior opposed
laterals
LDR 22.5–27Gy to point A
HDR¼high-dose rate; LDR¼low-dose rate; AP¼antero-posterior; PA¼postero-anterior; CT¼computer tomography; Cs¼caesium.
Table 5 Vaizey questionnaires (proportion of patients with positive results)
Gynaecology (% of all
gynaecology patients)
Urology (% of all
urology patients)
GI (% of all
gastrointestinal patients)
Total (% of all
patients)
Incontinent for solid stools 19 (31) 9 (15) 10 (45) 38 (22)
Incontinent for liquid stools 29 (47) 11 (19) 10 (45) 50 (35)
Incontinence for gas 36 (58) 22 (38) 12 (55) 70 (49)
Incontinence affecting lifestyle 19 (31) 7 (12) 6 (27) 32 (22)
Need to wear a pad or plug 10 (16) 2 (3) 4 (18) 16 (11)
Need for constipating
medicines
10 (16) 5 (9) 6 (27) 21 (15)
Cannot defer defecation for
15min
33 (53) 12 (21) 8 (36) 89 (63)
GI¼gastrointestinal.
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sgastrointestinal cancer (95% confidence intervals 28.2–71.8%),
and this was significantly more common (gynaecological vs
urology, P¼0.003 and GI vs urology, P¼0.026) than in the 24%
(95% confidence intervals 13.9–37.2%) patients who had been
treated for a urological cancer.
The median score on the Vaizey questionnaire was 3.5 (range 0–
24). In all, 46 patients had no faecal continence problems, if they
are excluded, and the other 96 patients had a median score of 5
(range 1–24).
The modified IBDQ
The results and range obtained from the IBDQ are shown in Tables
6a–d and Figure 1. The data suggest that 127 patients (89%) had
noticed a change of varying severity in their bowel habit. The
urology patients reported fewer symptoms than the gynaecology
and gastrointestinal patients.
The median score on the IBDQ for all the patients was 212
(range 101–224). Among the symptomatic patients, the median
score was 207 (range 101–223).
LENT SOMA questionnaire (Table 7)
The median score for all patients on the small intestine/colon
SOMA was 0.1538 (range 0–1) and the rectal SOMA median
score was 0.1428 (range 0–1). For those patients who were
symptomatic, the median score on the small intestine/colon SOMA
was 0.2307 (range 0.0769–1) and the rectal SOMA was 0.2143 (range
0.0714–1).
Correlations between IBDQ and Vaizey questionnaire with
LENT SOMA (Table 8)
The small intestine/colon SOMA median score was 0.1538
(range 0–1) and the rectal SOMA median score was 0.1428
(range 0–1). Pearson’s correlations for the IBDQ score and
small intestine/colon SOMA score was  0.630 (Po0.001),
IBDQ and rectum SOMA  0.616 (Po0.001), IBDQ and
Vaizey scores  0.599 (Po0.001), Vaizey and small intestine/colon
SOMA 0.452 (Po0.001) and Vaizey and rectum SOMA 0.760
(Po0.001).
Table 6 IBDQ (a) proportion of patients with bowel symptoms, (b) proportion of patients with systemic symptoms, (c) proportion of patients with
emotional symptoms and (d) proportion of patients with social symptoms
Gynaecology (% of all
gynaecology patients)
Urology (% of all
urology patients)
GI (% of all
gastrointestinal
patients)
Total (% of all
patients)
(a) IBDQ (proportion of patients with bowel symptoms)
Increase in bowel frequency 35 (56) 14 (24) 13 (59) 62 (44)
Loose motions 32 (52) 19 (32) 11 (50) 62 (44)
Pain in abdomen or bottom 30 (48) 9 (16) 4 (18) 43 (30)
Passing large amount of gas 31 (50) 23 (40) 12 (55) 66 (46)
Feeling of bloating 28 (45) 9 (16) 7 (32) 44 (31)
Rectal bleeding 14 (23) 9 (16) 5 (23) 28 (20)
Tenesmus 19 (31) 13 (22) 8 (36) 40 (28)
Accidental soiling 23 (37) 7 (2) 9 (41) 39 (27)
Feeling disgusted about bowel problems 12 (19) 1 (2) 3 (14) 16 (11)
(b) IBDQ (proportion of patients with systemic symptoms)
Felt tired and worn out 38 (61) 27 (47) 9 (41) 74 (52)
Worried about energy levels 35 (55) 19 (33) 6 (27) 59 (42)
Felt generally unwell 22 (35) 8 (14) 3 (14) 33 (23)
Waking at night or having difficulty sleeping 27 (44) 17 (29) 12 (55) 56 (39)
Worried about getting to the weight you would like 21 (34) 17 (29) 5 (23) 43 (30)
(c) IBDQ (proportion of patients with emotional symptoms)
Felt frustrated, impatient or restless 25 (40) 16 (27) 7 (32) 48 (34)
Worried about having something done about your
bowels
12 (8) 3 (2) 6 (27) 21 (15)
Worried about not being able to find a lavatory 13 (21) 9 (15) 8 (36 30 (21)
Been depressed or discouraged 20 (32) 14 (24) 8 (36) 42 (30)
Worried about your illness 23 (16) 12 (21) 7 (32) 42 (30)
Relaxed and free of tension 11 (18) 5 (9) 5 (23) 21 (15)
Been embarrassed about your bowels 18 (30) 6 (10) 3 (14) 27 (19)
Felt tearful or upset 18 (30) 8 (14) 8 (36) 34 (24)
Felt angry as a result of bowel problems 12 (19) 1 (2) 2 (9) 15 (11)
Felt irritable 30 (48) 12 (21) 6 (27) 48 (34)
Experienced lack of understanding from others 7 (11) 3 (5) 3 (14) 13 (9)
Not felt satisfied, happy or pleased with your life 14 (23) 3 (5) 1 (5) 18 (29)
(d) IBDQ (proportion of patients with social symptoms)
Unable to do what you want because of your bowels 22 (35) 5 (9) 4 (18) 31 (22)
Cancelled an engagement because of your bowels 7 (11) 1 (2) 2 (9) 10 (7)
Not done leisure or sport because of your bowels 14 (23) 2 (3) 3 (14) 19 (13)
Not gone somewhere because there is no lavatory
nearby
12 (19) 2 (3) 2 (9) 16 (11)
Limited in sexual activity because of your bowels 7 (11) 0 (0) 1 (5) 8 (6)
IBDQ¼Inflammatory Bowel Disease questionnaire; GI¼gastroinstestinal.
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sScores for patients with previous bowel surgery or chronic
gastrointestinal disorders
Of the 142 patients, 28 had had either a previous bowel disorder
or bowel surgery before commencement of radiotherapy.
These patients tended to have increased gastrointestinal
morbidity as defined by two questionnaires. Compared to
those without a previous gastrointestinal history, they
ad a median score of 5 instead of 1 (Vaizey) and a score of 0.21
vs 0.071 (small bowel/colon SOMA) and 0.15 vs 0.77
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Range of scores reported after completing the IBDQ 
Figure 1 Numbers of patients within each range of scores using the IBDQ.
Table 7 Scores of (a) the entire cohort using Vaizey, IBDQ and LENT SOMA and (b) only the symptomatic patients using Vaizey, IBDQ and LENT
SOMA
Gynaecology Urology GI Total
(a) Scores of the entire cohort using Vaizey, IBDQ and LENT SOMA
Vaizey
Median score 5 1 4 3.5
Range 0–24 0–16 0–22 0–24
IBDQ
Median score 196.5 218.5 214 212
Range 101–224 158–224 156–224 101–224
Small bowel SOMA
Median score 0.2307 0.7692 0.1923 0.1538
Range 0–1 0–0.4615 0–0.5385 0–1
Rectal SOMA
Median score 0.1786 0.0714 0.2143 0.1428
Range 0–1 0–0.7143 0–0.9286 0–1
(b) Scores of only the symptomatic patients using Vaizey, IBDQ and LENT SOMA
Vaizey
Median score 6 4 7.5 7.5
Range 1–24 1–16 2–23 1–24
IBDQ
Median score 191.5 215 213 207
Range 101–223 158–223 156–223 101–223
Small bowel SOMA
Median score 0.3076 0.1538 0.2307 0.2307
Range 0.0769–1 0.0769–0.5384 0.0769–0.5385 0.0769–1
Rectal SOMA
Median score 0.2143 0.1429 0.2143 0.2143
Range 0.0714–1 0.0714–0.7143 0.0714–0.9286 0.0714–1
IBDQ¼Inflammatory Bowel Disease questionnaire; LENT¼Late Effects on Normal Tissue; SOMA¼Subjective, Objective, Management and Analytic; GI¼gastroinstestinal.
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s(Rectal SOMA). However, they had an improved IBDQ score (213
vs 203).
DISCUSSION
This study shows that there is a highly significant correlation
between the degree of gastrointestinal dysfunction recorded in
patients who had completed pelvic radiotherapy at least 3 months
previously when two simple, patient self-administered question-
naires validated for benign diseases were used in comparison to
scores recorded when the staff administered LENT SOMA
questionnaire was used. Furthermore, these data suggest that
at least half of all patients who have received radiotherapy for a
pelvic tumour still suffer from bowel problems affecting their QOL
3 or more months after radiotherapy. The data suggest that
symptoms may be more common after therapeutic irradiation for
gynaecological and gastrointestinal tumours than for urological
tumours.
The optimal combination of surgery, chemotherapy and radio-
therapy for pelvic cancer is frequently controversial. In the past,
treatment choices have usually been recommended on the basis of
the likelihood of cure. And while cure clearly remains the central
issue, if there is a high likelihood of long-term survival and varying
regimens have equal likelihood of success, it becomes imperative
that long-term toxicity and effect of the treatment on QOL is also
considered. Robust data on the long-term gastrointestinal toxicity
of radiotherapy used to treat pelvic cancers are scanty. This is
mainly because the methods used to assess gastrointestinal toxicity
historically have been inadequate. More recent questionnaires
have proved too complex for clinical practice. The few prospective
studies that have used careful assessment have suggested that long-
term bowel toxicity is of the order we have documented here
(Lundby et al, 1997; Dahlberg et al, 1998; Kozelsky et al, 2003), but
the identification of patients with significant gastrointestinal
toxicity in clinical practice frequently remains inadequate.
These questionnaires identified bowel dysfunction in many
patients. The significance of this dysfunction is more difficult to
determine. Physicians’ perceptions of what constitutes severe
toxicity and its effect on QOL may differ from patients. The clinical
implications of an abnormal Vaizey score, however small, may be
significant for an individual patient. The whole cohort reported a
median Vaizey score of 3.5 and when the patients with no
incontinence were excluded, the median score was still only 5
(range 1–24). While this may seem modest, only two points can
mean the difference between a patient complaining of incontinence
to liquid stool ‘daily’ or ‘sometimes’. From a patient’s perspective,
this can mean the ability to do one’s own weekly shopping, or
relying on help from others, which may take on social implica-
tions. It is not clear why when 35% of patients are incontinent for
stools, only 23% feel that this incontinence affects their lifestyle.
On the other hand, faecal incontinence scores by themselves may
not be helpful. If a patient has severe urgency, but never leaves the
house, they may be rarely incontinent, but their QOL may be poor.
For example, 11% of our patients had not gone somewhere because
there was no lavatory nearby and 28% had been worried about
finding a lavatory when out.
The clinical implication of a single abnormal IBDQ score is also
unclear. However, there are excellent data from patients with
inflammatory bowel disease showing that if their disease is
quiescent, that they will consistently score their QOL within a
very narrow range of scores. Thus, if sequential scores deteriorate
with time, this is a reliable indicator of disease activity producing
gastrointestinal, systemic and psychological symptoms. This has
been demonstrated both in a primary-care setting as well as in
hospital practice (Guyatt et al, 1989; Yoshida, 1999; Cheung et al,
2000; Rubin et al, 2004). In other words, in the setting of benign
inflammatory disease, this questionnaire is highly reliable, and
while we have not tested the reproducibility of scores in patients
with stable symptoms in this study, there is little reason to think
that this group of patients should score change in symptoms
differently to those with inflammatory bowel disease. However,
this study suggests that in the symptomatic patients, the median
IBDQ score was 207 (range 101–223). Further research is required
to determine whether this means that symptoms were indeed
relatively minor or, as has been demonstrated before, that patients
minimise and accept their symptoms when they believe they are
the inevitable consequences of radiotherapy treatment, of being
old or that there is nothing that can be done (Faithfull, 1995).
Perhaps for the oncologist in clinical practice, the most useful
way therefore, to use the IBDQ and Vaizey questionnaires in
patients undergoing radiotherapy would be to record a score
before treatment starts and then record sequential scores, which if
deteriorating are likely to reflect significant gastrointestinal
morbidity. For patients in clinical trials, this study suggests that
the IBDQ may offer a significantly more sensitive indicator of
gastrointestinal disease and its effect on QOL than RTOG or LENT
SOMA.
LENT SOMA system tackles both objective and subjective
morbidity, and unlike IBDQ, attempts to integrate it with data
from clinical tests and medical interventions. However, it then
restricts its conclusions to one of five bands, which blunts its
sensitivity in describing subtle but potentially important problems.
In addition, it is difficult to use with 11% of patients failing to
complete their LENT SOMA questionnaire in one prospective
study (Routledge et al, 2003).
This study failed to recruit its target number of gastrointestinal
tumour patients because unusually low numbers of these patients
attended clinic over the 8 weeks during which this study was
carried out. Therefore in this group, who may have additional
gastrointestinal symptoms from their tumour or previous surgery,
it is particularly difficult to be sure that the IBDQ is a sensitive
measure of radiation toxicity. The reduced toxicity we noted in the
prostate patients may reflect that treatment for prostate cancer
leads to less volume of bowel exposed to radiotherapy. If this is the
case, it is interesting to speculate whether this advantage will be
maintained if IMRT becomes widely used. However, there is some
evidence that men may be more reluctant than women to report
gastrointestinal symptoms generally, and when they do report
them, it is generally at a lower level. Therefore, it is important not
Table 8 Pearson’s correlation
Small intestine SOMA score Rectum SOMA score Vaizey Score Total IBDQ score
Small intestine SOMA score 1 0.643 (**) 0.452 (**)  0.630 (**)
Rectum SOMA score 0.643 (**) 1 0.760 (**)  0.616 (**)
Vaizey score 0.452 (**) 0.760 (**) 1  0.599 (**)
Total IBDQ score  0.630 (**)  0.616 (**)  0.599 (**) 1
Significance level (two-tailed) o0.001 o0.001 o0.001 o0.001
IBDQ¼Inflammatory Bowel Disease questionnaire; SOMA¼Subjective, Objective, Management and Analytic; **Correlation is significant at the 0.01 level (two-tailed).
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report problems.
In summary, this study suggests that simple, long established
questionnaires used in benign gastroenterological diseases and
validated in primary-care and hospital settings and across cultural
divides appear to be applicable to oncological patients. Their
simplicity and precision makes them ideal for clinical practice to
identify patients who require specialist help or in the clinical
trial setting, to provide a sensitive measure of gastrointestinal
toxicity.
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